Atea Pharmaceuticals Announces Pricing of Initial Public Offering
October 29 2020 - 8:00PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing antiviral therapeutics to improve
the lives of patients suffering from life-threatening viral
infections, today announced the pricing of its initial public
offering of 12,500,000 shares of its common stock at a price to the
public of $24.00 per share. All of the shares of common stock are
being offered by Atea. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and estimated
offering expenses payable by Atea, are expected to be $300 million,
excluding any exercise of the underwriters’ option to purchase
additional shares. Atea’s common stock is expected to begin trading
on the Nasdaq Global Select Market under the ticker symbol “AVIR”
on October 30, 2020. The offering is expected to close on November
3, 2020, subject to satisfaction of customary closing conditions.
In addition, Atea has granted the underwriters a 30-day option to
purchase up to an additional 1,875,000 shares of Atea’s common
stock at the initial public offering price less the underwriting
discounts and commissions.
J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC,
Evercore Group L.L.C. and William Blair & Company, L.L.C. are
acting as joint book-running managers of the offering.
A registration statement on Form S-1 (File No. 333-249404)
relating to the offering has been filed with the Securities and
Exchange Commission and became effective on October 29, 2020. The
offering was made only by means of a prospectus. Copies of the
final prospectus relating to the offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, telephone:
866-803-9204; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd
Floor, New York, NY 10014, Attention: Prospectus Department, or by
email at prospectus@morganstanley.com; Evercore Group, L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; or William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by
email at prospectus@williamblair.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contacts
Investors:Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Media:Carol Guaccero301-606-4722contactus@ateapharma.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024